Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in korean adults: A randomized, double-blind, multicenter trial

Dae Won Park, Kyong Ran Peck, Moon Hyun Chung, Jin Seo Lee, Yoon Soo Park, Hyo Youl Kim, Mi Suk Lee, Jung Yeon Kim, Joon Sup Yeom, Ja Kim Min

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, doubleblinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.

Original languageEnglish
Pages (from-to)476-483
Number of pages8
JournalJournal of Korean Medical Science
Volume27
Issue number5
DOIs
Publication statusPublished - 2012 May 1

Fingerprint

Ceftriaxone
Pyelonephritis
Urinary Tract Infections
Multicenter Studies
Therapeutics
Drug-Related Side Effects and Adverse Reactions
ertapenem
Escherichia coli
Safety

Keywords

  • Ceftriaxone
  • Ertapenem
  • Pyelonephritis
  • Urinary tract infections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in korean adults : A randomized, double-blind, multicenter trial. / Park, Dae Won; Peck, Kyong Ran; Chung, Moon Hyun; Lee, Jin Seo; Park, Yoon Soo; Kim, Hyo Youl; Lee, Mi Suk; Kim, Jung Yeon; Yeom, Joon Sup; Min, Ja Kim.

In: Journal of Korean Medical Science, Vol. 27, No. 5, 01.05.2012, p. 476-483.

Research output: Contribution to journalArticle

Park, Dae Won ; Peck, Kyong Ran ; Chung, Moon Hyun ; Lee, Jin Seo ; Park, Yoon Soo ; Kim, Hyo Youl ; Lee, Mi Suk ; Kim, Jung Yeon ; Yeom, Joon Sup ; Min, Ja Kim. / Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in korean adults : A randomized, double-blind, multicenter trial. In: Journal of Korean Medical Science. 2012 ; Vol. 27, No. 5. pp. 476-483.
@article{48d44a521c104098bb9363b33daa65cc,
title = "Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in korean adults: A randomized, double-blind, multicenter trial",
abstract = "The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, doubleblinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9{\%}) in the ertapenem group and 71 (52.2{\%}) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9{\%}) patients in the ertapenem group and 63 (88.7{\%}) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.",
keywords = "Ceftriaxone, Ertapenem, Pyelonephritis, Urinary tract infections",
author = "Park, {Dae Won} and Peck, {Kyong Ran} and Chung, {Moon Hyun} and Lee, {Jin Seo} and Park, {Yoon Soo} and Kim, {Hyo Youl} and Lee, {Mi Suk} and Kim, {Jung Yeon} and Yeom, {Joon Sup} and Min, {Ja Kim}",
year = "2012",
month = "5",
day = "1",
doi = "10.3346/jkms.2012.27.5.476",
language = "English",
volume = "27",
pages = "476--483",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "5",

}

TY - JOUR

T1 - Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in korean adults

T2 - A randomized, double-blind, multicenter trial

AU - Park, Dae Won

AU - Peck, Kyong Ran

AU - Chung, Moon Hyun

AU - Lee, Jin Seo

AU - Park, Yoon Soo

AU - Kim, Hyo Youl

AU - Lee, Mi Suk

AU - Kim, Jung Yeon

AU - Yeom, Joon Sup

AU - Min, Ja Kim

PY - 2012/5/1

Y1 - 2012/5/1

N2 - The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, doubleblinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.

AB - The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, doubleblinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.

KW - Ceftriaxone

KW - Ertapenem

KW - Pyelonephritis

KW - Urinary tract infections

UR - http://www.scopus.com/inward/record.url?scp=84862898999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862898999&partnerID=8YFLogxK

U2 - 10.3346/jkms.2012.27.5.476

DO - 10.3346/jkms.2012.27.5.476

M3 - Article

C2 - 22563210

AN - SCOPUS:84862898999

VL - 27

SP - 476

EP - 483

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 5

ER -